Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.15 USD | -0.32% |
|
-6.16% | +23.66% |
06-04 | Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating | MT |
06-03 | Transcript : Crinetics Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.66% | 3.49B | |
+35.03% | 51.07B | |
-7.55% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+12.23% | 26.35B | |
-17.67% | 19.46B | |
+41.29% | 13.58B | |
+30.41% | 12.46B | |
-3.12% | 11.75B |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating